Vivoryon Therapeutics: Leadership Expected at Key Investor Conference in April
Vivoryon Therapeutics N.V., a clinical-stage biotechnology company, announces its management's participation in an investor conference scheduled for April 2026. Listed on Euronext Amsterdam, the company continues its regular dialogue with shareholders and analysts.
Vivoryon Therapeutics announces that Julia Neugebauer, PhD and Chief Operating Officer, will participate in the Van Lanschot Kempen Life Sciences Conference, which will be held in Amsterdam, Netherlands, on April 16, 2026. This participation is part of the company's ongoing dialogue with the investor community.
Focus on Innovative Drug Development
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Vivoryon Therapeutics is a clinical-stage biotechnology company focused on the development of innovative small molecules for the treatment of inflammatory and fibrotic kidney disorders. The company's most advanced program, varoglutamstat, is an orally administered, first-in-class QPCT/L inhibitor, currently under evaluation for the treatment of diabetic nephropathy.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Revenue: 0 M€
EBITDA: null
Net income: -8,853 M€
Free cash flow: -8,461 M€
Guidance from the release
Nous sommes très optimistes que nous réaliserons un partenariat stratégique.
Pas de revenus en 2025, mais une réflexion sur la stratégie de financement.
Risks mentioned
La Société devra lever des fonds supplémentaires pour financer ses opérations.
Les pertes d'exploitation continueront au cours de l'exercice financier 2026.
Opportunities identified
L'initiation de l'étude Phase 2b DKD est envisagée.
Les données de Phase 2 sont encouragées pour le développement futur.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
